Literature DB >> 9138435

Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?

D L Garver1, J L Steinberg, B E McDermott, J K Yao, J E Ramberg, S Lewis, S J Kingsbury.   

Abstract

The distribution of drug-free plasma homovanillic acid (pHVA) concentrations was studied in a sample of psychotic patients, some of whom were selected for good prognostic features. Baseline pHVA was bimodally distributed, suggesting two different patient populations. The high-pHVA patients showed periods of better functioning and/or fewer symptoms 5 years before admission (p < .05) and had a more rapid (p < .05) and complete (p < .001) subacute neuroleptic response than lower-pHVA psychotics. High-pHVA psychotics did not differ in other aspects of demographics or clinical presentation from lower-pHVA psychotics. Compared to the general population, there were more psychotics in the families of high-pHVA patients (p < .005). Rapid antipsychotic response by high-pHVA psychotics is consistent with blockade of the effects of excess synaptic dopamine at D2 receptors for these patients. Results are discussed in the context of the syndromic heterogeneity of the psychoses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138435     DOI: 10.1016/S0893-133X(96)00186-8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  3 in total

Review 1.  The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

Authors:  Ofer Agid; Phillip Seeman; Shitij Kapur
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

Review 2.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

3.  Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity.

Authors:  Robert D Oades; Bernd Röpcke; Uwe Henning; Ansgard Klimke
Journal:  Behav Brain Funct       Date:  2005-08-09       Impact factor: 3.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.